About Us

MK has nearly ten years of experience in protein therapeutics. Before joining BioLoomics, she was at Mosaic Biosciences, where she led multiple partner programs. MK completed her PhD in the Pharmacology Department at the Johns Hopkins School of Medicine with a focus on enzymology and chemical biology. She has significant experience purifying difficult-to-express proteins from numerous expression systems and a strong analytical background to develop assays for protein characterization, cellular signaling, and PK/PD measurements from animal samples

Jeremy operates at the intersection of mechanical and electrical engineering and data analysis with an emphasis on biological data sets. Prior to joining BioLoomics, he was an analyst for the DARPA Rapid Threat Assessment project at the University of Colorado, Boulder. He specializes in large multidimensional datasets and has applied this expertise to proteomics, metabolomics, and microscopy data. 

Ted has over 12 years of biotech industry experience, specializing in Manufacturing Science and Technology (MSAT). He has held process development and engineering positions at several industry-leading pharmaceutical companies. Ted relocated to Colorado from California in 2019 to co-found BioLoomics and lead the effort to streamline, standardize, and scale up BioLoomics’ laboratory operations.

Dr. Doug Chapnick is a veteran of cell biology with 20 years’ experience engineering in the life sciences space. He led technology development and research in the DARPA funded ‘Rapid Threat Assessment (RTA)’ project at the University of Colorado, Boulder. He founded BioLoomics to apply principles from the RTA project to overcome market-wide throughput limitations for activity-based discovery of antibodies. Doug received his PhD in Biochemistry from University of Colorado, Boulder, and has authored over 17 academic research publications ranging in focus from cell biology to drug mechanisms of action.

Mike is an experienced research biochemist coming from ArcherDX and Sartorius with expertise in developing high throughput assays for cell screening using a variety of techniques including NGS, microscopy, and flow cytometry. During his postdoctoral and graduate work at the University of Colorado Boulder, he studied the immune response to bacterial infection using FRET biosensors in primary macrophages. Mike is focused on bringing the drug discovery and downstream analysis of candidates to scale.

Karen has a background in art history, and throughout her career has developed a diverse skill set that includes bookkeeping, project management, grant reporting and copy editing. She draws upon experiences in multiple industries to support the people and organizational operations of BioLoomics.

Bill is a pharma and biotech veteran with extensive research and business development experience. He spent most of his career at AbbVie where he directed drug discovery programs in oncology, antivirals and antibacterials. He later led a global technology scouting team as part of the business development organization. Prior to joining BioLoomics in 2021 Bill was CEO of a start-up focused on Alzheimer’s disease and CSO of a Boston-based company offering fund-raising services to early-stage entrepreneurs.

Claire has over 10 years of experience as a research scientist, specializing in high-throughput assay development, cellular signaling, and single-cell fluorescence microscopy. During her PhD and postdoctoral work at the University of Colorado, she studied the molecular mechanisms driving cell-cycle commitment using single-cell timelapse microscopy of fluorescent biosensors. Claire specializes in driving forward the selection and validation of therapeutic antibody scaffolds via cell-based assay development, single-cell screening, and cell picking microscopy.

Rachel is an experienced molecular biologist coming from Inscripta with expertise in DNA repair and genetics. She is skilled at developing protocols for large-scale mutagenesis. During her postdoctoral work at the IBPC she developed a novel CRISPR-based protocol to study DNA replication and telomere regulation. At BioLoomics, Rachel is focused on optimizing and scaling library production to more efficiently identify drug candidates.

Humza is a Systems Biologist with knowledge and expertise in cell biology, computational biology, quantitative and high throughput, fluorescence microscopy, live-cell imaging, flow cytometry, single-cell analysis, and cancer biology. During his graduate work at the University of Colorado Boulder, he studied single-cell fate variability in the proliferative responses of cancer cells to acute chemotherapy treatment. Humza is passionate about leveraging novel tools and methods to extract meaningful insights into complex biological processes.

Kaitlyn holds a BS in Biochemistry from the University of Denver. She has experience implementing and creating quality control standards and protocols in the diagnostic industry. At BioLoomics, she supports our DNA and cell biology scientists with a wide range of daily tasks including solution preparation, experimental support at different stages, and inventory management. She's focused on developing industry skills in preparation for pursuing a graduate degree.